SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Adipokine dysregulation and adipose tissue inflammation in human obesity

    Unamuno X (1,2), Gómez-Ambrosi J (1,2,3), Rodríguez A (1,2,3), Berrecil S (1,2,3), Frühbeck G (1,2,3,4), Catalán V (1,2,3).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (4) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.

    European Journal of Clinical Investigation 11 JULY 2018

  • Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy

    Etxeberria I (1,2,3), Teijeira A (1,2,3), Montuenga LM (2,3,4), Berraondo P (1,2,3), Melero I (5,2,3,6).

    (1) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
    (4) Program of Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (5) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (6) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

    Cancer Discovery 03 JULY 2018

  • Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C

    Manzardo C (1), Londoño MC (1,2), Castells L (2,3), Testillano M (4), Montero J L (2,5), Peñafiel J (1), Subirana M (1), Moreno A (6), Aguilera V (7), González-Diéguez ML (8), Calvo-Pulido J (9), Xiol X (10), Salcedo M (11), Cuervas-Mons V (12), Sousa JM (13), Suarez F (14), Serrano T (15,16), Herrero JI (2,17), Jiménez M (18), Fernandez JR (4), Giménez C (9), Del Campo S (6), Esteban-Mur JI (2,3), Crespo G (1,2), Moreno A (1), de la Rosa G (19), Rimola A (1,2), Miro JM (1); FIPSE LT-HIV investigators.

    (1) Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona.
    (2) CIBEREHD.
    (3) Hospital Vall d'Hebrón, Universitat Autónoma de Barcelona, Barcelona.
    (4) Servicio de Digestivo. Hospital Universitario Cruces, Barakaldo.
    (5) Hospital Universitario Reina Sofía-IMIBIC Córdoba.
    (6) Hospital Universitario Ramón y Cajal-IRYCIS, Madrid.
    (7) Hospital Universitari La Fe, Valencia.
    (8) Hospital Universitario Central de Asturias, Oviedo.
    (9) Hospital Universitario Doce de Octubre, Madrid.
    (10) Hospital de Bellvitge-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona.
    (11) Hospital General Universitario Gregorio Marañón, Madrid.
    (12) Hospital Universitario Puerta de Hierro, Madrid.
    (13) Hospital Universitario Virgen del Rocío, Sevilla.
    (14) Complejo Hospitalario Universitario, A Coruña.
    (15) Hospital Universitario Lozano Blesa, ISS Aragón, Zaragoza.
    (16) Hospital Universitario Lozano Blesa, Zaragoza.
    (17) Clínica Universidad de Navarra, IdiSNA, Pamplona.
    (18) Hospital Universitario Carlos Haya, Málaga.
    (19) Organización Nacional de Trasplantes, Madrid.

    American Journal of Transplantation 02 JULY 2018

  • A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Walker BA (1), Mavrommatis K (2), Wardell CP (1), Ashby TC (1), Bauer M (1), Davies F (1), Rosenthal A (3), Wang H (3), Qu P (3), Hoering A (3), Samur M (4), Towfic F (5), Ortiz M (6), Flynt E (5), Yu Z (5), Yang Z (5), Rozelle D (7), Obenauer J (7), Trotter M (6(, Auclair D (8), Keats J (9), Bolli N (10), Fulciniti M (4), Szalat R (4), Moreau P (11), Durie B (12), Stewart AK (13), Goldschmidt H (14), Raab MS (14,15), Einsele H (16), Sonneveld P (17), San Miguel J (18), Lonial S (19), Jackson GH (20), Anderson KC (4), Avet-Loiseau H (21,22), Munshi N (4), Thakurta A (5), Morgan G (23).

    (1) Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
    (2) Celgene Corporation, San Francisco, CA, USA.
    (3) Cancer Research and Biostatistics, Seattle, WA, USA.
    (4) Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (5) Celgene Corporation, Summit, NJ, USA.
    (6) Celgene Institute of Translational Research Europe, Sevilla, Spain.
    (7) Rancho BioSciences, San Diego, CA, USA.
    (8) Multiple Myeloma Research Foundation, Norwalk, CT, USA.
    (9) Translational Genomics Research Institute, Phoenix, AZ, USA.
    (10) University of Milan, Milano, Italy.
    (11) University of Nantes, Nantes, France.
    (12) Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.
    (13) Department of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
    (14) Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
    (15) German Cancer Research Center (DKFZ), Heidelberg, Heidelberg, Germany.
    (16) Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany.
    (17) Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
    (18) Clinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (19) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (20) Department of Haematology, Newcastle University, Newcastle, UK.
    (21) Centre de Recherche en Cancérologie de Toulouse Institut National de a Santé et de la Recherche Médicale, U1037, Toulouse, France.
    (22) L'Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France.
    (23) Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

    Leukemia 02 JULY 2018

  • Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice

    Martinez-Martin P (1,2), Kulisevsky J (1,3), Mir P (1,4), Tolosa E (1,5), García-Delgado P (6), Luquin MR (7).

    (1) Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
    (2) National Center of Epidemiology, Carlos III Institute of Health, Madrid, Spain.
    (3) Department of Neurology, Movement Disorders Unit, Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Universitat Oberta de Catalunya (UOC), Barcelona, Spain.
    (4) Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
    (5) Movement Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
    (6) Grupo de Investigación en Atención Farmacéutica, Facultad de Farmacia, Universidad de Granada, Granada, Spain.
    (7) Department of Neurology, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.

    NPJ Parkinson's Disease 02 JULY 2018

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra